WO 2005/074916 PCT/EP2005/000758

CLAIMS

What is Claimed Is:

- 1. A method of treating a human suffering from an abnormal lipid distribution disorder, the method comprising administering to said subject a growth hormone and a statin-based therapeutic agent.
- 2. The method of claim 1, wherein said statin-based agent and said growth hormone are provided in a single pharmaceutical composition.
- 3. The method of claim 1, wherein said statin-based agent is provided in a first pharmaceutical composition and said growth hormone is provided in a second pharmaceutical composition.
- 4. The method of claim 1, wherein said growth hormone is recombinant growth hormone.
- 5. The method of claim 1, wherein said growth hormone has been isolated from an animal.
- 6. The method of claim 1, wherein said statin-based agent is a lovastatin or a lovastatin analog.
- 7. The method of claim 1, wherein said statin-based drug is selected from the group consisting of atorvastatin, pravastatin, simvastatin, lovastatin, and fluvastatin.
- 8. The method of claim 1, wherein said abnormal lipid distribution disorder is non-HIV-related lipodystrophy.

- 9. The method of claim 1, wherein said abnormal lipid distribution disorder is an HIV-related abnormal lipid distribution disorder.
- 10. The method of claim 9, wherein said HIV-related abnormal lipid distribution disorder is selected from the atherogenic dyslipidemia, hypertriglyceridemia, elevated levels of cholesterol, elevated levels of low-density-lipoprotein cholesterol, and low levels of high-density lipoprotein cholesterol.
- 11. The method of claim 1, wherein said subject manifests a symptom associated with diabetes related adiposity.
- 12. The method of claim 11, wherein said symptom is selected from the group consisting of insulin resistance, beta-cell dysfunction, loss of first phase insulin secretion, impaired glucose tolerance (IGT), elevated endogenous glucose production, excessive gluconeogenesis,
- 13. The method of claim 1, wherein said subject is suffering from Type 2 Diabetes.
- 14. The method of claim 11, wherein subject is further treated for diabetes, the method comprising administering an insulin secretagogue.
- 15. The method of claim 14, wherein said insulin secretagogue is selected from the group consisting of a sulphonylurea; tolbutamide; chlorpropamide; glimepiride; glipizide; glyburide; a meglitinides; repaglinide; pramlintide; morphilinoguanide; acetylcholine; a muscarinic agonist; carbachol; bethanechol; beta-L-glucose pentaacetate; chiro-inositol; myo-inositol; GIP; GLP-1; and Extendin-4.

- 16. The method of claim 15, wherein said insulin secretagogue is a non-glucose dependent insulin secretagogue, and the combined effect of administering said growth hormone, statin and insulin secretagogue produces insulin release patterns capable of attaining glucose dependent, bi-phasic release characteristics with reduced likelihood of producing hypoglycemia.
- 17. The method of claim 1, wherein said subject is further treated with leptin.
- 18. A therapeutic agent for use in combination therapy for an abnormal lipid distribution disorder, said composition comprising:
- a. a first composition comprising a recombinant growth hormone in a pharmaceutically acceptable carrier, excipient or diluent; and
- b. a second composition comprising a statin-based drug in a pharmaceutically acceptable carrier, excipient or diluent.
- 19. The therapeutic agent of claim 18, wherein said growth hormone and said statin-based drug are formulated in a single formulation.
- 20. The therapeutic agent of claim of claim 18, wherein said growth hormone is formulated in a separate formulation from said statin-based drug formulation.
- 21. The therapeutic agent of claim 20, wherein said growth hormone formulation and said statin-based drug formulation are formulated as injectable formulations.
- 22. The therapeutic agent of claim 20, wherein said statin-based drug formulation is formulated for oral administration.

WO 2005/074916 PCT/EP2005/000758

- 23. The therapeutic agent of claim 20, wherein said statin-based drug is a lovastatin or an analog thereof.
- 24. The therapeutic agent of claim 20, wherein said statin-based drug is selected from the group consisting of atorvastatin, pravastatin, simvastatin, lovastatin, and fluvastatin.